Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)
Latest Information Update: 15 Dec 2023
At a glance
- Drugs Nivolumab (Primary)
- Indications Meningeal carcinomatosis; Solid tumours
- Focus Adverse reactions
- 21 Oct 2022 Planned End Date changed from 30 Sep 2024 to 30 Sep 2026.
- 21 Oct 2022 Planned primary completion date changed from 30 Sep 2023 to 30 Sep 2025.
- 12 Nov 2021 New trial record